发明名称 Glycopegylated erythropoietin
摘要 The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
申请公布号 US8916360(B2) 申请公布日期 2014.12.23
申请号 US201113157575 申请日期 2011.06.10
申请人 Novo Nordisk A/S 发明人 DeFrees Shawn;Zopf David A.;Bowe Caryn Lang
分类号 C12P21/06;A61K38/18;A61P7/06;C07K14/505;A61K38/14;C12P21/00;A61K38/22;A61K38/00 主分类号 C12P21/06
代理机构 Leydig, Voit & Mayer, Ltd. 代理人 Leydig, Voit & Mayer, Ltd.
主权项 1. A cell-free, in vitro method of forming a covalent conjugate between an erythropoietin peptide and poly(ethylene glycol), which method comprises: (a) providing an erythropoietin peptide, (b) providing a modified sugar donor comprising an intact glycosyl linking group covalently linked to poly(ethylene glycol), wherein the intact glycosyl linking group has a structure according to the formula:wherein n is an integer from 0-500, and (c) covalently attaching the intact glycosyl linking group to a glycosyl or amino acid residue of the erythropoietin peptide by reaction between the erythropoietin peptide and the modified sugar donor, wherein the reaction is catalyzed by a sialyltransferase.
地址 Bagsvaerd DK